Cited by 4,154Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 300 of the 302 references it cites were found in a registry or an index.

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Open access

Waldman, Alex D., Fritz, Jill M., Lenardo, Michael J.·2020·Nature Reviews Immunology

DOI 10.1038/s41577-020-0306-5PMC PMC7238960

Open this paper in CoChat — free account Open PDF

Abstract

The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41577-020-0306-5

Cites

300 of 300 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–300 of 300

Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 366
Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line
Gross, L. (1943) · Cancer Research · Cited by 362
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
Tazdait, M., Mezquita, L., Lahmar, J., Ferrara, R., Bidault, F., Ammari, S., Balleyguier, C., Planchard, D., Gazzah, A., Soria, J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.017 · Cited by 354
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T. J., Allison, J. P., Bigner, D. D., & Sampson, J. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2070 · Cited by 343
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P. J., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 340
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335
Emerging targets in cancer immunotherapy
Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 320
Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response
Sharma, A., Subudhi, S. K., Blando, J. M., Vence, L. M., Wargo, J. A., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 317
Monoclonal antibodies identifying a novel T-Cell antigen and Ia antigens of human lymphocytes
Hansen, J. A., Martin, P. J., & Nowinski, R. C. (1980) · Immunogenetics · doi:10.1007/bf01561573 · Cited by 314
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Koneru, M., O'Cearbhaill, R. E., Pendharkar, S., Spriggs, D. R., & Brentjens, R. J. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0460-x · Cited by 309
Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis
Nishijima, T. F., Shachar, S. S., Nyrop, K. A., & Muss, H. B. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0419 · Cited by 307
The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A
Chuang, E., Fisher, T. S., Morgan, R. W., Robbins, M. D., Duerr, J. M., Vander Heiden, M. G., Gardner, J. P., Hambor, J. E., Neveu, M. J., & Thompson, C. B. (2000) · Immunity · doi:10.1016/s1074-7613(00)00031-5 · Cited by 303
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Vonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D. K., Soulières, D., Dorazio, P., Trosko, J. A., Rüter, J., Mariani, G. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0505 · Cited by 301
Human Ig superfamily CTLA‐4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA‐4 cytoplasmic domains
Dariavach, P., Mattéi, M., Golstein, P., & Lefranc, M. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181206 · Cited by 301
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300
Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen).
Hara, T., Fu, S. M., & Hansen, J. A. (1985) · The Journal of Experimental Medicine · doi:10.1084/jem.161.6.1513 · Cited by 280
The full spectrum of human naive T cells
van den Broek, T., Borghans, J. A. M., & van Wijk, F. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0001-y · Cited by 273
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Friedline, R. H., Brown, D. S., Nguyen, H., Kornfeld, H., Lee, J., Zhang, Y., Appleby, M. W., Der, S. D., Kang, J., & Chambers, C. A. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20081811 · Cited by 266
Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
Tai, X., Laethem, F. V., Pobezinsky, L. A., Guinter, T. I., Sharrow, S. O., Adams, A., Granger, L. G., Kruhlak, M. J., Lindsten, T., Thompson, C. B., et al. (2012) · Blood · doi:10.1182/blood-2011-11-388918 · Cited by 263
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
Brignone, C., Gutierrez, M., Mefti, F., Brain, E. G. C., Jarcau, R., Cvitkovic, F., Bousetta, N., Médioni, J., Gligorov, J., Grygar, C., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-71 · Cited by 259
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Chang, Z. L., Lorenzini, M. H., Chen, X., Tran, U., Bangayan, N. J., & Chen, Y. Y. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2565 · Cited by 259
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
Kuhn, N. F., Purdon, T. J., van Leeuwen, D. G., Lopez, A. V., Curran, K. J., Daniyan, A. F., & Brentjens, R. J. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.006 · Cited by 255
Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
Decker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 254
Inflammation and immune surveillance in cancer
Chow, M. T., Möller, A., & Smyth, M. J. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.004 · Cited by 253
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
Jain, N., Nguyen, H., Chambers, C. A., & Kang, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910341107 · Cited by 253
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0011-0 · Cited by 253
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
Kramer, K., Kushner, B. H., Modak, S. I., Pandit-Taskar, N. D., Smith-Jones, P. M., ZANZONICO, P. B., Humm, J. L., Xu, H. W., Wolden, S. L., Souweidane, M. M., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0038-7 · Cited by 247
Developing neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 241
Adoptive T Cell Immunotherapy For Cancer
Perica, K., Varela, J. C., Oelke, M., & Schneck, J. P. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10179 · Cited by 240
MHC Class II epitope predictive algorithms
Nielsen, M., Lund, O., Buus, S., & Lundegaard, C. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03268.x · Cited by 237
Peripheral T Cell Tolerance
MILLER, J. F. A. P., & Morahan, G. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.000411 · Cited by 219
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0342-x · Cited by 219
The Effects of TLR Activation on T-Cell Development and Differentiation
Jin, B., Sun, T., Yu, X., Yang, Y., & Yeo, A. E. T. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/836485 · Cited by 209
Improving the safety of cell therapy products by suicide gene transfer
Jones, B. S., Lamb, L. S., Goldman, F. D., & Stasi, A. D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00254 · Cited by 206
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A., & Tötterman, T. H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c01fcb · Cited by 198
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang, Y., Zou, J.-P., Mu, J., Wijesuriya, R., Ono, S., Walunas, T. L., Bluestone, J. A., Fujiwara, H., & Hamaoka, T. (1997) · PubMed · Cited by 197
A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes.
Martin, P. J., Ledbetter, J. A., Morishita, Y., June, C. H., Beatty, P., & Hansen, J. A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.9.3282 · Cited by 196
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance
Palmer, D. C., Guittard, G. C., Franco, Z., Crompton, J. G., Eil, R. L., Patel, S. J., Ji, Y., van Panhuys, N., Klebanoff, C. A., Sukumar, M., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150304 · Cited by 196
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
Kjærgaard, J., Tanaka, J., Kim, J. A., Rothchild, K. B., Weinberg, A. D., & Shu, S. (2000) · PubMed · Cited by 193
Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4
Wilkie, S., Papa, S., Chiapero-Stanke, L., Pereira, A. C. P., Cleary, S., van der Stegen, S. J. C., Spicer, J. F., Davies, D. M., & Maher, J. F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127951 · Cited by 189
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
He, Y., Rivard, C. J., Rozeboom, L. M., Yu, H., Ellison, K. E., Kowalewski, A. A., Zhou, C., & Hirsch, F. R. (2016) · Cancer Science · doi:10.1111/cas.12986 · Cited by 187
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
Shahabi, V., Berman, D., Chasalow, S. D., Wang, L., Tsuchihashi, Z., Hu, B., Panting, L., Jure‐Kunkel, M., & Ji, R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-75 · Cited by 186
CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice
Tivol, E. A., Boyd, S. D., Mckeon, S., Borriello, F., Nickerson, P. W., Strom, T. B., & Sharpe, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.11.5091 · Cited by 185
Development of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 179
Self-citation
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
Deng, W., Mao, L., Yu, G., Bu, L., Ma, S., Liu, B., Gutkind, J. S., Kulkarni, A. B., Zhang, W., & Sun, Z. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1239005 · Cited by 178
Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells
Brocker, T. (2000) · Blood · doi:10.1182/blood.v96.5.1999 · Cited by 173
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
Liu, Y., & Zheng, P. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.003 · Cited by 163
The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function
Alexander, D. R. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0218 · Cited by 154
Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells
Halliday, G. M., Patel, A., Hunt, M. J., Tefany, F. J., & Barnetson, R. S. (1995) · World Journal of Surgery · doi:10.1007/bf00299157 · Cited by 153
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
Hernandez, I., Prasad, V. K., & Gellad, W. F. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0977 · Cited by 153
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers
Prasad, V. K., Kaestner, V., & Mailankody, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4182 · Cited by 144
B7-1 or B7-2 Is Required to Produce the Lymphoproliferative Phenotype in Mice Lacking Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4)
Mandelbrot, D. A., McAdam, A. J., & Sharpe, A. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.435 · Cited by 142
Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4
Lee, S., Moon, J. S., Lee, C., Kim, H., Baek, S.-M., Hwang, S., Kang, G. H., Seo, J. K., Shin, C. H., Kang, H. J., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.036 · Cited by 133
Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 132
Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
Curran, M. A., & Allison, J. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3289 · Cited by 132
Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.
Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2505 · Cited by 129
Differential Effects of IL-12 on Tregs and Non-Treg T Cells: Roles of IFN-γ, IL-2 and IL-2R
Zhao, J., Zhao, J., & Perlman, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046241 · Cited by 126
Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine
He, Y., Zhang, G., Wang, X., Zhang, H., Yuan, Y., Li, D., & Feng, Z. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4919 · Cited by 125
Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer
van Schalkwyk, M. C., Papa, S., Jeannon, J., Urbano, T. G., Spicer, J. F., & Maher, J. F. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.144 · Cited by 125
A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells
Hou, T. Z., Qureshi, O., Wang, C. J., Baker, J., Young, S. P., Walker, L. S. K., & Sansom, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401876 · Cited by 123
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 123
Regulation of Cytotoxic T Lymphocyte-Associated Molecule-4 by Src Kinases
Chuang, E., Lee, K.-M., Robbins, M. D., Duerr, J. M., Alegre, M.-L., Hambor, J. E., Neveu, M. J., Bluestone, J. A., & Thompson, C. B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1270 · Cited by 119
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Furness, A. J. S., Vargas, F. A., Peggs, K. S., & Quezada, S. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.002 · Cited by 119
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade
Rauch, D. A., Conlon, K. C., Janakiram, M., Brammer, J. E., Harding, J. C., Ye, B. H., Zang, X., Ren, X., Olson, S. L., Cheng, X., et al. (2019) · Blood · doi:10.1182/blood.2019002038 · Cited by 113
Surface Cytotoxic T Lymphocyte–associated Antigen 4 Partitions Within Lipid Rafts and Relocates to the Immunological Synapse under Conditions of Inhibition of T Cell Activation
Darlington, P. J., Baroja, M. L., Chau, T. A., Siu, E., Ling, V., Carreno, B. M., & Madrenas, J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011868 · Cited by 109
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
Powderly, J. D., Cote, G. M., Flaherty, K. T., Szmulewitz, R. Z., Ribas, A., Weber, J. S., Loo, D. T., Baughman, J. E., Chen, F., Moore, P. A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o8 · Cited by 107
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects
Heicappell, R., Schirrmacher, V., von Hoegen, P., Ahlert, T., & Appelhans, B. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910370416 · Cited by 106
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
He, M., Chai, Y., Qi, J., Zhang, C. W. H., Tong, Z., Shi, Y., Yan, J., Tan, S., & Gao, G. F. (2017) · Oncotarget · doi:10.18632/oncotarget.18004 · Cited by 105
CTLA‐4 is required by CD4 + CD25 + Treg to control CD4 + T‐cell lymphopenia‐induced proliferation
Sojka, D. K., Hughson, A. L., & Fowell, D. J. (2009) · European Journal of Immunology · doi:10.1002/eji.200838603 · Cited by 103
Effect of leukocytes on transplantability of human cancer
Southam, C. M., Brunschwig, A., LEVIN, A. G., & Dizon, Q. S. (1966) · Cancer · doi:10.1002/1097-0142(196611)19:11 · Cited by 102
Pillars Article: CTLA-4 Can Function as a Negative Regulator of T Cell Activation. Immunity. 1994. 1: 405–413
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (2011) · The Journal of Immunology · doi:10.1093/ji/187.7.3466 · Cited by 100
How does the kinase Lck phosphorylate the T cell receptor? Spatial organization as a regulatory mechanism
Rossy, J., Williamson, D. J., & Gaus, K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00167 · Cited by 96
T‐cell antigen receptor signal transduction
Cantrell, D. A. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01391.x · Cited by 95
Induction of autoimmune disease in CTLA-4 −/− mice depends on a specific CD28 motif that is required for in vivo costimulation
Tai, X., Laethem, F. V., Sharpe, A. H., & Singer, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706509104 · Cited by 94
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
Decker, W. K., & Safdar, A. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.07.004 · Cited by 91
A 45‐kDa human T‐cell membrane glycoprotein functions in the regulation of cell proliferative responses
Gmünder, H., & Lesslauer, W. (1984) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1984.tb08263.x · Cited by 83
Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy
Hung, C., Xu, X., Li, L., Ma, Y., Qiu, J. F., Viley, A. M., Allen, C., Natarajan, P., Shivakumar, R., Peshwa, M. V., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.080 · Cited by 82
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion
Sharma, N., Vacher, J., & Allison, J. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819004116 · Cited by 75
Next generation immune-checkpoints for cancer therapy
Donini, C., D’Ambrosio, L., Grignani, G., Aglietta, M., & Sangiolo, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.79 · Cited by 74
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
Liu, J., Blake, S. J., Smyth, M. J., & Teng, M. W. L. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.18 · Cited by 72
T-cell receptor structure and TCR complexes
Wilson, I. A., & García, K. C. (1997) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(97)80156-x · Cited by 72
Personalized cancer vaccines: Targeting the cancer mutanome
Zhang, X., Sharma, P. K., Goedegebuure, S. P., & Gillanders, W. E. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.073 · Cited by 72
Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.
Schindler, K., Harmankaya, K., Kuk, D., Mangana, J., Michielin, O. A., Höeller, C., Dummer, R., Pehamberger, H., Wolchok, J. D., & Postow, M. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9096 · Cited by 71
Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
Burke, S., Shergold, A. L., Elder, M. J., Whitworth, J., Cheng, X., Jin, H., Wilkinson, R. W., Harper, J. A., & Carroll, D. K. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02495-x · Cited by 68
Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine.
Hanna, M. G., & Peters, L. C. (1978) · PubMed · Cited by 66
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
Berman, D., Korman, A. J., Peck, R., Feltquate, D., Lönberg, N., & Canetta, R. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.017 · Cited by 65
T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation
Lesslauer, W., Koning, F., Ottenhoff, T. H. M., Giphart, M. J., Goulmy, E., & van Rood, J. J. (1986) · European Journal of Immunology · doi:10.1002/eji.1830161017 · Cited by 56
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study
Moskowitz, C. H., Zinzani, P. L., Fanale, M. A., Armand, P. A., Johnson, N. A., Radford, J. A., Ribrag, V., Molin, D. L., Vassilakopoulos, T. P., Tomita, A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1107.1107 · Cited by 53
Neoplastic paneth cells.Their occurrence in 2 adenomas and one carcinoma of the colon
Holmes, E. J. (1965) · Cancer · doi:10.1002/1097-0142(196511)18:11 · Cited by 50
Effective anti‐metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with newcastle disease virus (NDV)
Plaksin, D., Porgador, A., Vadai, E., Feldman, M., Schirrmacher, V., & Eisenbach, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590615 · Cited by 42
Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro
Batchu, R. B., Gruzdyn, O. V., Mahmud, E. M., Chukr, F. K., Dachepalli, R., Manmari, S. K., Mostafa, G., Weaver, D. W., & Gruber, S. A. (2018) · Surgery · doi:10.1016/j.surg.2017.10.056 · Cited by 38
Restimulation‐induced cell death: new medical and research perspectives
Zheng, L., Li, J., & Lenardo, M. J. (2017) · Immunological Reviews · doi:10.1111/imr.12535 · Cited by 34
Self-citation
Predicting Tumor Response to PD-1 Blockade
Ding, L., & Chen, F. (2019) · New England Journal of Medicine · doi:10.1056/nejmcibr1906340 · Cited by 34
Expression of CTLA‐4 and FOXP3 in cis protects from lethal lymphoproliferative disease
Chikuma, S., & Bluestone, J. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737159 · Cited by 32
Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature.
Tolcher, A. W., Alley, E. W., Chichili, G. R., Baughman, J. E., Moore, P. A., Bonvini, E., Vasselli, J. R., Wigginton, J. M., & Powderly, J. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps3105 · Cited by 27
Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in combination with ixabepilone in preclinical tumor models
Jure‐Kunkel, M., Masters, G. R., Girit, E., Dito, G., & Lee, F. Y. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3048 · Cited by 20
The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System
Moon, E. K., Langer, C. J., & Albelda, S. Μ. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201702-152fr · Cited by 20
Untitled work
(1999) · doi:10.1002/(sici)1521-4141(199903)29:03

Flagged first, then by citations

2 of the 302 references couldn’t be matched to a known paper.

Sorted by citations

Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordão, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,718
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
Metastasis
Gerstberger, S. C., Jiang, Q., & Ganesh, K. (2023) · Cell · doi:10.1016/j.cell.2023.03.003 · Cited by 1,010
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 986

See all 4,154

Authors: Waldman, A. D., Fritz, J. M., & Lenardo, M. J.
Affiliations: National Institutes of Health (US)
Corresponding author: Lenardo, Michael J.
ORCID: Waldman, Alex D.
Fritz, Jill M.
Lenardo, Michael J.
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2020-05-20
Volume: 20
Issue: 11
Pages: 651-668
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/s41577-020-0306-5
PMC: PMC7238960
OpenAlex: W3028523516
Cited by: 4,154
References: 302
Citations by year: 2026: 382 · 2025: 748 · 2024: 867 · 2023: 824 · 2022: 754 · 2021: 511 · 2020: 59
FWCI: 58.00
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Emory University
National Institutes of Health
National Institute of General Medical Sciences (T32GM008169)
National Institute of Allergy and Infectious Diseases
NHLBI Division of Intramural Research
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, T cells, T cell regulation, immune checkpoint blockade, adoptive cellular therapy, clinical trials, immunotherapy toxicity, history of cancer immunotherapy
MeSH terms: Immune Checkpoint Inhibitors, Animals, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks